1 O’Connell FP, "Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract" 129 : 338-347, 2005
2 Bayrak R, "The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody" 7 : 9-, 2012
3 Taal BG, "The spectrum of gastrointestinal metastases of breast carcinoma: II. the colon and rectum" 38 : 136-141, 1992
4 Qu Q, "The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer" 12 : 93-, 2014
5 Schwarz RE, "Metastatic breast cancer masquerading as gastrointestinal primary" 93 : 111-114, 1998
6 Gown AM, "Markers of metastatic carcinoma of breast origin" 68 : 86-95, 2016
7 Shimada H, "Japanese Gastric Cancer Association Task Force for research promotion: clinical utility of 18Fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature" 14 : 13-21, 2011
8 Turner NH, "HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact" 39 : 947-957, 2013
9 Curtit E, "Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis" 18 : 667-674, 2013
10 Taal BG, "Clinical presentation, endoscopic features, and treatment of gastric metastases from breast carcinoma" 89 : 2214-2221, 2000
1 O’Connell FP, "Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract" 129 : 338-347, 2005
2 Bayrak R, "The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody" 7 : 9-, 2012
3 Taal BG, "The spectrum of gastrointestinal metastases of breast carcinoma: II. the colon and rectum" 38 : 136-141, 1992
4 Qu Q, "The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer" 12 : 93-, 2014
5 Schwarz RE, "Metastatic breast cancer masquerading as gastrointestinal primary" 93 : 111-114, 1998
6 Gown AM, "Markers of metastatic carcinoma of breast origin" 68 : 86-95, 2016
7 Shimada H, "Japanese Gastric Cancer Association Task Force for research promotion: clinical utility of 18Fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature" 14 : 13-21, 2011
8 Turner NH, "HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact" 39 : 947-957, 2013
9 Curtit E, "Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis" 18 : 667-674, 2013
10 Taal BG, "Clinical presentation, endoscopic features, and treatment of gastric metastases from breast carcinoma" 89 : 2214-2221, 2000
11 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012" 대한암학회 47 (47): 127-141, 2015
12 McLemore EC, "Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis" 12 : 886-894, 2005
13 Aurilio G, "A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases" 50 : 277-289, 2014